Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor‐positive, HER2‐negative metastatic breast cancer: A real‐world multicenter study

Abstract Background Chidamide is a selective histone deacetylase inhibitor approved for patients with hormone receptor (HoR)‐positive and HER2‐negative metastatic breast cancer (MBC). We aimed to investigate the efficacy, safety, and treatment patterns of chidamide and identify clinicopathological f...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Doudou Li, Yizi Jin, Mingxi Lin, Cheng Zeng, Qing Guo, Yanfei Liu, Jian Zhang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2024-02-01
Colecção:	Cancer Medicine
Assuntos:	chidamide endocrine therapy hormone receptor‐positive metastatic breast cancer real‐world data
Acesso em linha:	https://doi.org/10.1002/cam4.6762
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!